Hepatitis; List Of Clinical Trials Updated Jan 31 2011

[Guest guest]

Hepatitis; List Of Clinical Trials Updated Jan 31 2011

Hepatitis Clinical Trials, Diagnosis, and TreatmentThank you for your interest in clinical trials for Hepatitis.Go to Clinical connection and enter your zip code to find the locations closest to you.http://www.clinicalconnection.com/Updated;Jan 31 2011A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01193478-19139Conditions: HCV InfectionLocation: Philadelphia, PAA Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01193478-20010Conditions: HCV InfectionLocation:

Washington, DCA Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01193478-32720Conditions: HCV InfectionLocation: Deland, FLA Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01193478-32809Conditions: HCV InfectionLocation: Orlando, FLA Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01193478-33169Conditions: HCV InfectionLocation: Miami, FLA Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01193478-63104Conditions: HCV InfectionLocation: St. Louis, MOA Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01193478-77030Conditions: HCV InfectionLocation: Houston, TXA Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01193478-78215Conditions: HCV InfectionLocation: San , TXA Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01193478-90630Conditions: HCV InfectionLocation: Cypress, CAA Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01193478-91950Conditions: HCV InfectionLocation: National City, CAA Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01193478-92801Conditions: HCV InfectionLocation: Anaheim, CAA Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01193478-97239Conditions: HCV InfectionLocation: Portland, ORA Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C - NCT01193478-98418Conditions: HCV InfectionLocation: Tacoma, WAA Network & Dyad HIV Prevention Intervention for IDU's - 1 - NCT00218335-21231Conditions: HIV - HepatitisLocation: Baltimore, MDA Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM3) - NCT00959699-02114Conditions: HIV Infections - Hepatitis C - HCV InfectionLocation: Boston, MAA Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM3) - NCT00959699-07102Conditions: HIV Infections - Hepatitis C - HCV InfectionLocation: Newark, NJA Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM3) - NCT00959699-10021Conditions: HIV Infections - Hepatitis C - HCV InfectionLocation: New York, NYA Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM3) - NCT00959699-14642Conditions: HIV Infections - Hepatitis C - HCV InfectionLocation: Rochester, NYA Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM3) - NCT00959699-21093Conditions: HIV Infections - Hepatitis C - HCV InfectionLocation: Lutherville, MDA Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM3) - NCT00959699-23298Conditions: HIV Infections - Hepatitis C

- HCV InfectionLocation: Richmond, VAA Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM3) - NCT00959699-34209Conditions: HIV Infections - Hepatitis C - HCV InfectionLocation: Brandenton, FLA Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM3) - NCT00959699-45267Conditions: HIV Infections - Hepatitis C - HCV InfectionLocation: Cincinnati, OHA Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM3) -

NCT00959699-92103Conditions: HIV Infections - Hepatitis C - HCV InfectionLocation: San Diego, CAA Phase II Study to Determine the Safety and Efficacy of Interferon-gamma in Patients With Chronic Hepatitis B - NCT00753467-91105Conditions: Hepatitis BLocation: Pasadena, CAA Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-02114Conditions: Chronic Hepatitis B Virus, PediatricLocation: Boston, MAA Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection -

NCT01079806-02115Conditions: Chronic Hepatitis B Virus, PediatricLocation: Boston, MAA Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-02903Conditions: Chronic Hepatitis B Virus, PediatricLocation: Providence, RIA Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-06106Conditions: Chronic Hepatitis B Virus, PediatricLocation: Hartford, CTA Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection

- NCT01079806-10029Conditions: Chronic Hepatitis B Virus, PediatricLocation: New York, NYA Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-19104Conditions: Chronic Hepatitis B Virus, PediatricLocation: Philadelphia, PAA Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-20010Conditions: Chronic Hepatitis B Virus, PediatricLocation: Washington, DCA Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic

HBV-Infection - NCT01079806-21287Conditions: Chronic Hepatitis B Virus, PediatricLocation: Baltimore, MDA Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-22031Conditions: Chronic Hepatitis B Virus, PediatricLocation: Fairfax, VAA Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-28203Conditions: Chronic Hepatitis B Virus, PediatricLocation: Charlotte, NCA Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With

Chronic HBV-Infection - NCT01079806-30322Conditions: Chronic Hepatitis B Virus, PediatricLocation: Atlanta, GAA Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-32610Conditions: Chronic Hepatitis B Virus, PediatricLocation: Gainesville, FLA Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-46202Conditions: Chronic Hepatitis B Virus, PediatricLocation: Inidanapolis, INA Phase III Study of the Safety and Efficacy of Entecavir in Pediatric

Patients With Chronic HBV-Infection - NCT01079806-77030Conditions: Chronic Hepatitis B Virus, PediatricLocation: Houston, TXA Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-94143Conditions: Chronic Hepatitis B Virus, PediatricLocation: San Francisco, CAA Pilot Study of High-Dose, Intravenous Ascorbic Acid (Vitamin C) to Treat Hepatitis C - NCT01250743-66160Conditions: Hepatitis CLocation: Kansas City, KSA Pilot Study of the Grapefruit Flavonoid Naringenin for HCV Infection -

NCT01091077-02114Conditions: Hepatitis C Virus - HCV Infection - Chronic HCV - Hepatitis CLocation: Boston, MAA Pilot Study to Examine the Role of Nitazoxanide to Prevent Recurrence of Hepatitis C After Transplantation - NCT01074203-55905Conditions: Hepatitis C RecurrenceLocation: Rochester, MNA Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-10016Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: New York, NYA Randomized Study to Evaluate the Safety, Tolerability and

Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-10021Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: New York, NYA Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-19141Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Philadelphia, PAA Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-21287Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Baltimore, MDA Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-23249Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Richmond, VAA Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-27599Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Chapel Hill, NCA Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 -

NCT01074008-27705Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Durham, NCA Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-32803Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Orlando, FLA Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-32809Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Orlando, FLA Randomized Study

to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-33136Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Miami, FLA Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-46202Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Indianapolis, INA Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-48202Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Detroit, MIA Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-53792Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Madison, WIA Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-55114Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: St. , MNA Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-60611Conditions:

Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Chicago, ILA Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-60612Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Chicago, ILA Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-63104Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: St. Louis, MOA Randomized Study to Evaluate the Safety, Tolerability and

Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-70112Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: New Orleans, LAA Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-70808Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Baton Rouge, LAA Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-75203AConditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Dallas, TXA Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-75203BConditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Dallas, TXA Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-77030Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Houston, TXA Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-78215Conditions:

Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: San , TXA Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-80045Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Aurora, COA Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-84132Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Salt Lake City, UTA Randomized Study to Evaluate the Safety,

Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-85054Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Phoenix, AZA Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-90048Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Los Angeles, CAA Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-92037Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: La Jolla, CAA Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-92801Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Anaheim, CAA Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-98101Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1Location: Seattle, WAA Randomized Trial of Vaccine Adherence in Young Injection Drug Users - 1 - NCT00244374-94143Conditions: Adherence - Community Outreach - HIV Risk

Behaviors - Hepatitis A Vaccines - Hepatitis B Vaccines - Hepatitis C - Needle-Exchange Programs - Substance Abuse, IntravenousLocation: San Francisco, CAA Randomized, Controlled Trial of Fluvastatin Added to Pegylated Interferon and Ribavirin (PI+R) Versus PI+R Alone for Treatment of Chronic Hepatitis C Not Previously Treated - NCT00487318-73104Conditions: Chronic Hepatitis CLocation: OKlahoma City, OKA Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I - NCT01142700-19141Conditions: Chronic Hepatitis C Virus Genotype 1Location: Philadelphia, PAA Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I - NCT01142700-20010Conditions: Chronic Hepatitis C Virus Genotype 1Location: Washington, DCA Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I - NCT01142700-20707Conditions: Chronic Hepatitis C Virus Genotype 1Location: Laurel, MDA Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus)

in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I - NCT01142700-23602Conditions: Chronic Hepatitis C Virus Genotype 1Location: Newport News, VAA Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I - NCT01142700-30060Conditions: Chronic Hepatitis C Virus Genotype 1Location: Mareitta, GAA Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I - NCT01142700-32803Conditions: Chronic Hepatitis C Virus Genotype 1Location: Orlando, FLA Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I - NCT01142700-33319Conditions: Chronic Hepatitis C Virus Genotype 1Location: Tamarac, FLA Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I - NCT01142700-34243Conditions: Chronic Hepatitis C Virus Genotype 1Location: Sarasota, FLA Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus)

in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I - NCT01142700-75246Conditions: Chronic Hepatitis C Virus Genotype 1Location: Dallas, TXA Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I - NCT01142700-92105Conditions: Chronic Hepatitis C Virus Genotype 1Location: San Diego, CAA Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I - NCT01142700-92118Conditions: Chronic Hepatitis C Virus Genotype 1Location: Coronado, CAA Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-02114Conditions: Hepatitis C, ChronicLocation: Boston, MAA Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-07601Conditions: Hepatitis C, ChronicLocation: Hackensack, NJA Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD))

and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-08234Conditions: Hepatitis C, ChronicLocation: Egg Harbour Township, NJA Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-10016Conditions: Hepatitis C, ChronicLocation: New York, NYA Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-13210Conditions:

Hepatitis C, ChronicLocation: Syracuse, NYA Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-22031Conditions: Hepatitis C, ChronicLocation: Fairfax, VAA Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-22908Conditions: Hepatitis C, ChronicLocation: Charlottesville, VAA Study of

Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-23249Conditions: Hepatitis C, ChronicLocation: Richmond, VAA Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-27103Conditions: Hepatitis C, ChronicLocation: Winston-salem, NCA Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid

Viral Response. - NCT00623428-27599Conditions: Hepatitis C, ChronicLocation: Chapel Hill, NCA Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-28801Conditions: Hepatitis C, ChronicLocation: Asheville, NCA Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-30060Conditions: Hepatitis C, ChronicLocation: Marietta, GAA Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-30308Conditions: Hepatitis C, ChronicLocation: Atlanta, GAA Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-32256Conditions: Hepatitis C, ChronicLocation: ville, FLA Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a

(40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-32803Conditions: Hepatitis C, ChronicLocation: Orlando, FLA Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-35294Conditions: Hepatitis C, ChronicLocation: Birmingham, ALA Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-37660Conditions:

Hepatitis C, ChronicLocation: Kingsport, TNA Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-38801Conditions: Hepatitis C, ChronicLocation: Tupelo, MSA Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-63104Conditions: Hepatitis C, ChronicLocation: St Louis, MOA Study of Combination

Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-63110Conditions: Hepatitis C, ChronicLocation: St Louis, MOA Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-70520Conditions: Hepatitis C, ChronicLocation: Opelousas, LAA Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. -

NCT00623428-70890Conditions: Hepatitis C, ChronicLocation: Baton Rouge, LAA Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-73112Conditions: Hepatitis C, ChronicLocation: Oklahoma City, OKA Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-78234Conditions: Hepatitis C, ChronicLocation: Fort Sam Houston, TXA Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-80045Conditions: Hepatitis C, ChronicLocation: Aurora, COA Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-84132Conditions: Hepatitis C, ChronicLocation: Salt Lake City, UTA Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a

(40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-87131Conditions: Hepatitis C, ChronicLocation: Albuquerque, NMA Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-90048Conditions: Hepatitis C, ChronicLocation: Los Angeles, CAA Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. -

NCT00623428-90057Conditions: Hepatitis C, ChronicLocation: Los Angeles, CAA Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-90505Conditions: Hepatitis C, ChronicLocation: Torrance, CAA Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-90822Conditions: Hepatitis C, ChronicLocation: Long Beach, CAA Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-92037Conditions: Hepatitis C, ChronicLocation: La Jolla, CAA Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-92103Conditions: Hepatitis C, ChronicLocation: San Diego, CAA Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD))

and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-93534Conditions: Hepatitis C, ChronicLocation: Lancaster, CAA Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-95816Conditions: Hepatitis C, ChronicLocation: Sacramento, CAA Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-95817Conditions:

Hepatitis C, ChronicLocation: Sacramento, CAA Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-96813Conditions: Hepatitis C, ChronicLocation: Honolulu, HIA Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-97239Conditions: Hepatitis C, ChronicLocation: Portland, ORA Study of Danoprevir

Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-02905Conditions: Hepatitis C, ChronicLocation: Providence, RIA Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-10021Conditions: Hepatitis C, ChronicLocation: New York, NYA Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-10468Conditions: Hepatitis C, ChronicLocation: Bronx, NYA Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-11030Conditions: Hepatitis C, ChronicLocation: Manhasset, NYA Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-21093Conditions: Hepatitis C, ChronicLocation: Lutherville, MDA Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic

Hepatitis C Virus Infection - NCT01220947-23602Conditions: Hepatitis C, ChronicLocation: Newport News, VAA Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-27599Conditions: Hepatitis C, ChronicLocation: Chapel Hill, NCA Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-28304Conditions: Hepatitis C, ChronicLocation: Fayetteville, NCA

Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-30033Conditions: Hepatitis C, ChronicLocation: Decatur, GAA Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-32804Conditions: Hepatitis C, ChronicLocation: Orlando, FLA Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-32809Conditions: Hepatitis C, ChronicLocation:

Orlando, FLA Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-33143Conditions: Hepatitis C, ChronicLocation: South Miami, FLA Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-37211Conditions: Hepatitis C, ChronicLocation: Nashville, TNA Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive

Patients With Chronic Hepatitis C Virus Infection - NCT01220947-48202Conditions: Hepatitis C, ChronicLocation: Detroit, MIA Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-60637Conditions: Hepatitis C, ChronicLocation: Chicago, ILA Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-70112Conditions: Hepatitis C, ChronicLocation: New Orleans, LAA Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-77030Conditions: Hepatitis C, ChronicLocation: Houston, TXA Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-78215Conditions: Hepatitis C, ChronicLocation: San , TXA Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-78234Conditions: Hepatitis C,

ChronicLocation: Fort Sam Houston, TXA Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-80045Conditions: Hepatitis C, ChronicLocation: Aurora, COA Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-92037Conditions: Hepatitis C, ChronicLocation: La Jolla, CAA Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus

in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-92123Conditions: Hepatitis C, ChronicLocation: San Diego, CAA Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-92154Conditions: Hepatitis C, ChronicLocation: San Diego, CAA Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-94143Conditions: Hepatitis C, ChronicLocation: San Francisco, CAA Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-95817Conditions: Hepatitis C, ChronicLocation: Sacramento, CAA Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection - NCT01220947-96817Conditions: Hepatitis C, ChronicLocation: Honolulu, HIA Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic

Hepatitis C Virus Infection - NCT01220947-97504Conditions: Hepatitis C, ChronicLocation: Medford, ORA Study of Early Immunologic Response in Asian Patients With Chronic Hepatitis B, Treated With Pegasys (Peginterferon Alfa-2a (40KD)), Nucleoside Analogues, or Both - NCT00962871-94143Conditions: Hepatitis B, ChronicLocation: San Francisco, CAA Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection - NCT00423891-02115Conditions: Hepatitis B, ChronicLocation: Boston, MAA Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus

(HBV)-Infection - NCT00423891-02903Conditions: Hepatitis B, ChronicLocation: Providence, RIA Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection - NCT00423891-06106Conditions: Hepatitis B, ChronicLocation: Hartford, CTA Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection - NCT00423891-10029Conditions: Hepatitis B, ChronicLocation: New York, NYA Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection - NCT00423891-19104Conditions: Hepatitis B, ChronicLocation:

Philadelphia, PAA Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection - NCT00423891-21287Conditions: Hepatitis B, ChronicLocation: Baltimore, MDA Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection - NCT00423891-32610Conditions: Hepatitis B, ChronicLocation: Gainesville, FLA Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection - NCT00423891-75390Conditions: Hepatitis B, ChronicLocation: Dallas, TXA Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection - NCT00423891-94143Conditions: Hepatitis B, ChronicLocation: San Francisco, CAA Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area - NCT00913757-Conditions: Carcinoma, Hepatocellular - Liver Cirrhosis, Alcoholic - Hepatitis, Alcoholic - Hepatitis, Chronic - Hepatitis, Viral, HumanLocation: Baltimore, MDA Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area - NCT00913757-20892Conditions: Carcinoma, Hepatocellular - Liver Cirrhosis,

Alcoholic - Hepatitis, Alcoholic - Hepatitis, Chronic - Hepatitis, Viral, HumanLocation: Bethesda, MDA Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area - NCT00913757-21205Conditions: Carcinoma, Hepatocellular - Liver Cirrhosis, Alcoholic - Hepatitis, Alcoholic - Hepatitis, Chronic - Hepatitis, Viral, HumanLocation: Baltimore, MDA Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-02905Conditions: Hepatitis C, ChronicLocation: Providence, RIA Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-10021Conditions: Hepatitis C, ChronicLocation: New York, NYA Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-11030Conditions: Hepatitis C, ChronicLocation: Manhasset, NYA Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic

Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-21093Conditions: Hepatitis C, ChronicLocation: Lutherville, MDA Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-23249Conditions: Hepatitis C, ChronicLocation: Richmond, VAA Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-27599Conditions: Hepatitis C, ChronicLocation: Chapel Hill, NCA Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-37211Conditions: Hepatitis C, ChronicLocation: Nashville, TNA Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-78215Conditions: Hepatitis C, ChronicLocation: San , TX

http://Hepatitis Cnewdrugs.blogspot.com/2011/01/hepatitis-c-list-of-clinical-trials.html